Biogen (NASDAQ: BIIB) reported Q2 EPS of $4.02, $0.24 better than the analyst estimate of $3.78. Revenue for the quarter came in at $2.46 billion versus the consensus estimate of $2.37 billion.

GUIDANCE:

Biogen sees FY2023 EPS of $15.00-$16.00, versus the consensus of $15.43.

• Total revenue Mid-single digit percentage decline

For earnings history and earnings-related data on Biogen (BIIB) click here.